NWA
PVLA

Navis Wealth Advisors’s Palvella Therapeutics PVLA Stock Holding History

Navis Wealth Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$18K – 96
2022
Q3 		$18K Hold
200
– – 0.03% 78
2022
Q2 		$30K Hold
200
– – 0.03% 95
2022
Q1 		$48K Hold
200
– – 0.04% 102
2021
Q4 		$60K Hold
200
– – 0.05% 102
2021
Q3 		$83K Hold
200
– – 0.06% 122
2021
Q2 		$61K Hold
200
– – 0.05% 102
2021
Q1 		$41K Hold
200
– – 0.03% 108
2020
Q4 		$40K Buy
+200
New +$41.6K 0.04% 145

Other funds holding PVLA

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Navis Wealth Advisors's PVLA Position: Q4 2022 in Review

Navis Wealth Advisors sold out of Palvella Therapeutics (PVLA) in Q4 2022, closing a stake of 200 shares — an estimated $18K sold.

Navis Wealth Advisors first reported a position in PVLA in Q4 2020 and held it in 8 quarters. The position peaked at $83K in Q3 2021. 63 funds tracked by Wall St. Rank hold PVLA as of Q4 2022.

  • Navis Wealth Advisors reported no remaining Palvella Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Navis Wealth Advisors sold 200 Palvella Therapeutics shares in Q4 2022, an estimated $18K.
  • Navis Wealth Advisors first reported a position in Palvella Therapeutics in Q4 2020 and held it in 8 quarters.
  • Navis Wealth Advisors's Palvella Therapeutics position peaked at $83K in Q3 2021.
  • 63 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2022.

Based on Navis Wealth Advisors's 13F filing for Q4 2022, filed 25 Jan 2023.